Treasing on Tylvamyco® as a Novel Immunomodulatory Medication on Broiler Chickens
Present study aims at the evaluation of the efficacy of Tylvamyco® as a new macrolides generation in control of avian mycoplasmosis in broilers chickens with special attention to its immunomodulation effects. A total of 500 day old broiler Ross 308 chicks were equally subdivided into two treatments of 250 birds in each. The Tylvamyco® treated group, and the control non treated group were kept in a separate house. Blood samples and tracheal tissues collected at one day old and also each week till the end of the trials for isolation M. gallisepticum and also measuring the immune status of the experimental chicks. M.gallisepticum occurrence rate in broilers chickens was 12% which confirmed by PCR. The minimal inhibitory concentration values Tylvamyco® against recovered 12 M.gallisepticum isolates standard strain showed that the Tylvamyco® has MIC90 value of 0.008. In the Tylvamyco® treated group the immune status profiles record that there are marked increase in the immunological parameters by age as; HI test results for Mycoplasma ,NDV , AI, INF-γ conc. ,IL-6 conc. ,Phagocytic cell count ,Nitric oxide conc. and Lysozyme conc. at 1, 15, 30 day old respectively. The molecular analysis of CXCL8 gene as an indicator for inflammation reduction potency in In the Tylvamyco® treated group by using real-time PCR showed that the Cycle Threshold of CXCL8 gene reduced by age from 13.6 to 10.7 at 15 day old and 30 day old with fold change 0.57 and 1.4 respectively. Performance parameter in Tylvamyco® treated group as 3.22 kg/bird, with mean weight gain 2.33 kg/bird and feed conversion rate 1.4. The mortality rate was 5% with slight air saculitis, as post-mortum records, in conclusion our study proved that Tylvamyco® act as a potent immunomodulatory medication in broilers.